Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 13

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 13
---
 expect that any proceeds received by us from such sales tothe Selling
Shareholder will be usedto fund our development programs, for working capital and other
general corporate purposes.

We have the right to terminate the Purchase Agreement at any time, upon one business days’ notice, at no cost or penalty. During any “suspension event” under the Purchase Agreement,the Selling Shareholder does not have the right to terminate the Purchase Agreement; however, we may not initiate any regular or other purchase of shares bythe
Selling Shareholder, until such event of default is cured. In addition, in the event of bankruptcy proceedings by or against us, the Purchase Agreement will automatically terminate in accordance with its terms.

There are substantial risks to our shareholders as a result of the sale and issuance of Depositary Shares tothe Selling Shareholder
under the Purchase Agreement. These risks include substantial dilution, significant declines in our stock price and our inability to draw sufficient funds when needed. See “ Risk Factors.” The sale of our Depositary Shares tothe Selling Shareholder under the Purchase Agreement will not affect the rights or privileges of our other shareholders, except that the economic and voting interests of our existing shareholders will be diluted as a result of any such sale. Although the number of Depositary Shares that our other shareholders own will not decrease, the shares owned by our other shareholders will represent a smaller percentage of our total outstanding shares after any such sale tothe Selling
Shareholder under the Purchase Agreement.

For more information see “ The Committed Equity Financing.”

| 5 |

Promissory Note

On December 20, 2024, or the
Issuance Date, we issued a promissory note to the Selling Shareholder in the aggregate principal amount of $600,000, or the Note, at a
10% original issue discount. The Note is an unsecured obligation of the Company and bears interest at an annual rate of 5%, which may
be increased under certain circumstances, and has a maturity date of one year from the Issuance Date. The Note includes a monthly repayment
schedule, with the entire principal amount of the Note, plus accrued and unpaid interest, due and payable by the Company on the date that
is twelve (12) months from the Issuance Date, or the Maturity Date. The Note may be prepaid prior to the Maturity Date without penalty.
Additionally, during the term of the Note, if we conduct a securities offering with gross proceeds equal to or greater than $500,000